KR900011772A - 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘 - Google Patents

3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘 Download PDF

Info

Publication number
KR900011772A
KR900011772A KR1019900000626A KR900000626A KR900011772A KR 900011772 A KR900011772 A KR 900011772A KR 1019900000626 A KR1019900000626 A KR 1019900000626A KR 900000626 A KR900000626 A KR 900000626A KR 900011772 A KR900011772 A KR 900011772A
Authority
KR
South Korea
Prior art keywords
hydrogen
alkyl
atom
compound
hydroxy
Prior art date
Application number
KR1019900000626A
Other languages
English (en)
Other versions
KR920010642B1 (ko
Inventor
유겐 매코어 죤
Original Assignee
알렌 제이.스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이.스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이.스피겔
Publication of KR900011772A publication Critical patent/KR900011772A/ko
Application granted granted Critical
Publication of KR920010642B1 publication Critical patent/KR920010642B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(I)의 화합물 및 약제학적으로 허용되는 그의 염.
    (I)
    상기식에서, A,B,D 및 E중의 하나는 N원자이며, 나머지 3개는 C원자이고, R1및 R2는 독립적으로 수소 및 C1내지 C6알킬로부터 선택되며, R3,R|4,R5및 R6는 독립적으로 수소, 할로겐, 하이드록시, C1-C6알킬, C1-C8알콕시, 페닐-C1-C6알콕시, 페녹시, -NR7R8(여기서, R7및 R8은 독립적으로 수소, C1-C|6알킬, C1-C6알카노일, 및 COOR9(여기서, R9는 수소 또는 C1-C6알킬이다)로부터 선택도이다〕, 시아노, COOR10(여기서, R10은 수소 또는 C1-C6알킬이다) , 및 CONR11R12(여기서, R11및 R12은 독립적으로 수소 및 C1-C8알킬로부터 선택된다)로부터 선택된다.
  2. 제1항에 있어서, R1,R2,R5및 R6가 수소이고, R3는 부재하며, R4는 제1항에서 정의된 바와같고, A는 N원자이며, B,D 및 E는 C원자인 화합물.
  3. 제1항 또는 제2항에 있어서, R7가 수소, 메톡시, 에톡시, 프로폭시, 부톡시, 또는 하이드록시인 화합물.
  4. 비만증, 우울증 또는 공격적인 증후 치료 유효량의 제1항에 따른 화합물 및 약제학적으로 허용되는 담체를 포함하는 비만증, 우울증 또는 공격적인 증후가 나타나는 질환 치료용 약제학적 조성물.
  5. 제4항에 있어서, R1,R2,R5및 R6가 수소이고, R3는 부재하며, R4는 제1항에서 정의된 바와같고, A는 N원자이며, B,D 및 E는 C원자인 조성물.
  6. 제4항 또는 5항에 있어서, R4가 수소, 메톡시, 에톡시, 프로폭시, 부톡시 또는 하이드록시인 조성물.
  7. 비만증, 우울증 또는 공격적인 증후 되료 유효량의 제1항 내지 제3항중 어느 한 항에 따른 화합물을 비만증, 우울증 또는 공격적인 증후가 나타나는 질환의 치료를 필요로하는 포유동물에게 투여함을 특징으로 하여 포유동물의 상기 질환을 치료 또는 예방하는 방법.
  8. 제7항에 있어서, R1,R2,R5및 R6가 수소이고, R3는 부재하며, R4는 제1항에서 정의된 바와같고, A는 N원자이며, B,D 및 E는 C원자인 방법.
  9. 제7항 또는 제8항에 있어서, R4가 수소, 메톡시, 프로폭시, 부톡시 또는 하이드록시인 방법.
  10. 하기 일반식(ⅡA)의 화합물.
    (ⅡA)
    상기식에서, R4는 수소, 할로겐, 하이드록시, C1-C6알킬, C1-C|8알콕시, 페닐-C1-C6알콕시, 페녹시, -NR7R8〔여기서, R7및 R8은 독립적으로 수소, C1-C6알킬, C1-C6알카노일, 및 COOR9(여기서, R9는 수소 또는 C1-C6얼칼이다)로부터 선택된다〕시아노, COOR10(여기서, R10은 수소 또는 C1-C6알킬이다), 및 CONR|11R12(여기서, R11및 R12은 독립적으로 수소 및 C1-C6알킬로부터 선택된다)로부터 선택된다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900000626A 1989-01-20 1990-01-19 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘 KR920010642B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US89/00231 1989-01-20
USP4/US8900231 1989-01-20
PCT/US1989/000231 WO1990007926A1 (en) 1989-01-20 1989-01-20 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines

Publications (2)

Publication Number Publication Date
KR900011772A true KR900011772A (ko) 1990-08-02
KR920010642B1 KR920010642B1 (ko) 1992-12-12

Family

ID=22214793

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900000626A KR920010642B1 (ko) 1989-01-20 1990-01-19 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘

Country Status (26)

Country Link
US (2) US5051412A (ko)
EP (1) EP0379314B1 (ko)
JP (1) JPH0751576B2 (ko)
KR (1) KR920010642B1 (ko)
CN (1) CN1025998C (ko)
AT (1) ATE103282T1 (ko)
CA (1) CA2008016A1 (ko)
CS (1) CS277611B6 (ko)
DD (2) DD298398A5 (ko)
DE (1) DE69007501T2 (ko)
DK (1) DK0379314T3 (ko)
EG (1) EG18945A (ko)
ES (1) ES2062319T3 (ko)
FI (1) FI94641C (ko)
HU (1) HU206349B (ko)
IE (1) IE62757B1 (ko)
IL (1) IL93041A (ko)
MX (1) MX19185A (ko)
MY (1) MY106305A (ko)
NO (1) NO912860D0 (ko)
NZ (1) NZ232166A (ko)
PL (2) PL163626B1 (ko)
PT (1) PT92889A (ko)
WO (1) WO1990007926A1 (ko)
YU (1) YU47553B (ko)
ZA (1) ZA90393B (ko)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007926A1 (en) * 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5451566A (en) * 1993-11-17 1995-09-19 Zeneca Limited Herbicidal pyrrolopyridine compounds
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP1082958A3 (en) * 1996-11-15 2002-12-11 Eli Lilly And Company 5-HT1F agonists in chronic pain
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ZA989389B (en) * 1997-11-14 2000-04-14 Lilly Co Eli Pyrrolo [3,2-b] pyridine processes and intermediates.
US5905084A (en) * 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
JP4616009B2 (ja) 2002-12-26 2011-01-19 ポーゼン インコーポレイテッド ＮＳＡＩＤｓおよびトリプタンを含有する多層剤型
RU2006121990A (ru) * 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
BRPI0513916A (pt) 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de pirrol-piridina cinase
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
CA2656364C (en) 2006-07-06 2014-11-25 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
ATE523499T1 (de) 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
PL2114955T3 (pl) * 2006-12-29 2013-06-28 Rigel Pharmaceuticals Inc Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
TWI450720B (zh) 2007-07-05 2014-09-01 Array Biopharma Inc 作為ａｋｔ蛋白質激酶抑制劑之嘧啶環戊烷
US8377937B2 (en) * 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2009204025B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2401685T3 (es) * 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
JP5858789B2 (ja) 2009-01-16 2016-02-10 ライジェル ファーマシューティカルズ， インコーポレイテッド 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬
PE20120508A1 (es) 2009-06-17 2012-05-09 Vertex Pharma Inhibidores de la replicacion de los virus de la gripe
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CN103874689B (zh) 2011-04-01 2016-04-27 基因泰克公司 Akt抑制剂化合物和威罗菲尼的组合及使用方法
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
SG10201804021TA (en) 2013-11-13 2018-07-30 Vertex Pharma Methods of preparing inhibitors of influenza viruses replication
WO2016062790A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
CN107074881B (zh) 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的噻吩并嘧啶衍生物
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272804A (en) * 1963-12-23 1966-09-13 Sterling Drug Inc Process and intermediates for preparing indoles
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
IL48508A (en) * 1974-12-09 1979-10-31 Roussel Uclaf Pharmaceutical compositions comprising piperidylindole derivatives
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
FR2444678A2 (fr) * 1978-12-22 1980-07-18 Roussel Uclaf Nouveau procede de preparation de derives du piperidyl-indole et de leurs sels
US5025096A (en) * 1985-08-22 1991-06-18 Mine Safety Appliances Company Preparation of indole and indole derivatives
WO1990007926A1 (en) * 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines

Also Published As

Publication number Publication date
EP0379314A1 (en) 1990-07-25
PT92889A (pt) 1990-07-31
AU613259B2 (en) 1991-07-25
NO912860L (no) 1991-07-22
HU206349B (en) 1992-10-28
FI94641B (fi) 1995-06-30
NZ232166A (en) 1992-10-28
FI94641C (fi) 1995-10-10
EG18945A (en) 1994-09-29
CN1025998C (zh) 1994-09-28
CS26090A3 (en) 1992-02-19
MY106305A (en) 1995-04-29
IL93041A0 (en) 1990-11-05
DE69007501D1 (de) 1994-04-28
EP0379314B1 (en) 1994-03-23
FI913509A0 (fi) 1991-07-22
DD298398A5 (de) 1992-02-20
HUT57762A (en) 1991-12-30
ZA90393B (en) 1991-08-28
DK0379314T3 (da) 1994-05-09
WO1990007926A1 (en) 1990-07-26
PL163626B1 (pl) 1994-04-29
CS277611B6 (en) 1993-03-17
MX19185A (es) 1993-12-01
CA2008016A1 (en) 1990-07-20
PL287840A1 (en) 1991-07-15
YU47553B (sh) 1995-10-03
ATE103282T1 (de) 1994-04-15
AU4867390A (en) 1990-07-26
JPH02247175A (ja) 1990-10-02
IE62757B1 (en) 1995-02-22
JPH0751576B2 (ja) 1995-06-05
DE69007501T2 (de) 1994-06-30
NO912860D0 (no) 1991-07-22
IE900210L (en) 1990-07-23
US5051412A (en) 1991-09-24
US5169947A (en) 1992-12-08
CN1044465A (zh) 1990-08-08
DD291559A5 (de) 1991-07-04
ES2062319T3 (es) 1994-12-16
KR920010642B1 (ko) 1992-12-12
PL283354A1 (en) 1991-08-12
IL93041A (en) 1994-02-27
YU9990A (en) 1992-05-28

Similar Documents

Publication Publication Date Title
KR900011772A (ko) 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘
KR950002755A (ko) 워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제
KR950031068A (ko) 골다공증의 복합 치료
KR920008024A (ko) 퀴놀린 유도체
KR920021556A (ko) 라파 마이신 이량체
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950017949A (ko) 벤조티오펜 화합물과 수용성 사이클로덱스트린의 수용성 내포착물, 및 그의 약학제제 및 제조 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
KR950016735A (ko) 터너 증후군의 억제 방법
KR890014107A (ko) 백금 화학 요법약제
KR950016729A (ko) 유방 질환의 억제 방법
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR900018027A (ko) 피페리딘 유도체, 그의 제조 방법, 및 그것을 유효성분으로 함유하는 의약용 조성물
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법
KR910004557A (ko) 2,4,6-치환 페놀 유도체
KR880012586A (ko) 새로운 피리딜 및 피리미딜 유도체
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee